Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Convincing Data Needed to Perpetuate Premium for New Drug Development: Mr Yoshida of MED
March 13, 2012
- Gov’t Releases Some Documents Related to Draft Statement on Iressa Lawsuits
March 13, 2012
- MHLW Announces Requirements for “Clinical Research Core Hospitals”
March 12, 2012
- Study Group to Discuss Whether “ABC” Screening Should Be Included in Gastric Cancer Screening: Parliamentary Secretary Fujita
March 9, 2012
- DPJ’s PAL Subcommittee to Begin Compiling Recommendations in Mid-March; Timing of Bill Unclear
March 7, 2012
- Aricept to Receive 16.7-16.8% Reduction, Lyrica 25% in Re-Pricing Due to Market Expansion
March 6, 2012
- 702 Products Including DPP-4 Inhibitors to Be Eligible for New Drug Premium in April
March 5, 2012
- Private-Sector Members of Strategy Council Call for Early Establishment of Drug Discovery Support Organization
March 5, 2012
- Cancer Policy Promotion Council Submits New 5-Year Plan to Health Minister Komiyama
March 5, 2012
- Revised Ordinance Banning “Dispensing Point” Services Announced in Official Gazette
March 5, 2012
- 11 APIs/28 Products to Receive Premiums for New Pediatric, Orphan Indications
March 5, 2012
- PAFSC’s 2nd Committee on Drugs Recommends Approval for Pfizer Japan’s ALK Inhibitor Xalkori
March 1, 2012
- MHLW Study Group Approves Outline of “Post-5-Year Plan” for Promoting Clinical Trials
March 1, 2012
- PAFSC’s 2nd Committee on Drugs Recommends Orphan Drug Designation for 4 Products
February 29, 2012
- MHLW Conducts Hearing on Distribution Improvement with Drug Manufacturers
February 28, 2012
- Ikoma City Introduces Pharmacy Certification System to Promote Use of Generics
February 28, 2012
- Non-partisan Study Group Holds Hearings on Problem of Essential But Unprofitable Drugs
February 28, 2012
- Next 5-Year Strategy Calls for Boost to Japanese“Rising Sun”Seed Development
February 27, 2012
- PAFSC’s First Committee on Drugs Recommends Approval for Eli Lilly’s Once-Weekly GLP-1 Receptor Agonist
February 27, 2012
- National, Rosai Hospitals Hold 1st Meeting Aimed at Joint Purchasing in July
February 27, 2012
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…